Somerset, NJ –October 30, 2014 — A team of senior drug development and delivery experts from Catalent Pharma Solutions (Booth 1414), will lead multiple thought-leadership discussions, present scientific papers, and exhibit at the forthcoming 2014 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, which runs from November 2nd to 6th at the San Diego Convention Center, San Diego, CA. Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products.
On Sunday November 2nd, from 9:00am to 9:30am, Irena McGuffy, Director, Formulation Development, will present “Quality by Design in Lipid Formulation and Processing" as part of the “Improving Oral Bioavailability By Lipid-Based Delivery” track. She will be followed, from 10:00am to 10:30am, by David Fulper, Director Technology Support, who will discuss "Stability and Process Considerations for Lipid Systems." Ms. McGuffy will then participate in “Track V: Recent Developments,” which takes place from 10:45 am until 3:30 pm.
Also on November 2nd, from 1:00 pm to 1:40 pm, Daniel Peizer, Director, Animal Health will present “New Tricks for Old Dogs - Focus on Zydis® Technology" as part of the ‘Health Drug R&D Workshop: Formulation, Delivery and Development to Market.’ His session will examine how innovative drug delivery technologies can improve the delivery of existing and new animal health treatments.
On Monday, November 3rd, Catalent will host a seminar from 1:30pm to 4:30pm in Room 1A. "Formulation Solutions Using Hot Melt Extrusion for Poorly Soluble Drugs" will discuss, in depth, the formulation development of hot melt extruded oral solid dosage forms with Catalent’s OptiMelt™ platform. It will cover guidance on selection and screening of polymers/excipients for formulation development and strategies for scale-up of hot melt extruded products, followed by a world class panel discussion with industry leaders.
In addition to the presentations and seminar, Catalent will also present eighteen scientific papers at the AAPS meeting on a broad spectrum of topics including determination of API crystalline state in hot melt extrudate formulations, enhanced oral bioavailability of a poorly soluble drug, and evaluation of empirical thermodynamic solubility modeling in formulation vehicles.
To arrange a meeting with any of the Catalent team at AAPS, please contact Richard Kerns at NEPR: email@example.com.
Catalent Pharma Solutions is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,000 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and in fiscal 2014 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com